Compass Pathways' Psilocybin Drug Meets Primary Endpoint in Phase 3 Trial Despite Market Disappointment
Key Insights
Compass Pathways' synthetic psilocybin drug COMP360 achieved its primary endpoint in a Phase 3 trial for treatment-resistant depression (search), showing a 3.6-point greater symptom reduction versus placebo.
The results met the predefined goal of at least a 3-point difference but fell short of Wall Street's expectations for a 5-point improvement, leading to a nearly 50% stock decline.
The company has two additional Phase 3 trials ongoing with 26-week readouts expected in 2026, which could provide crucial data for FDA approval.
Compass Pathways faced a significant market setback following the release of Phase 3 trial results for its synthetic psilocybin drug COMP360, despite the treatment meeting its primary endpoint for treatment-resistant depression (search). The London-based biotechnology company's shares plunged nearly 50% on Monday, June 23, after the COMP005 trial showed a modest 3.6-point improvement in symptom reduction compared to placebo.
Trial Results Meet Primary Endpoint
The Phase 3 COMP005 trial enrolled 258 adults with treatment-resistant depression (search) and successfully achieved its predefined primary endpoint of at least a 3-point difference in symptom reduction. Patients receiving COMP360 demonstrated a 3.6-point greater reduction in symptoms versus those receiving placebo. However, this improvement fell short of the 5-point gap that Wall Street analysts had anticipated, triggering the sharp stock correction.
The trial results represent a critical milestone for psychedelic medicine, as companies in this emerging sector use substances like psilocybin to develop alternative treatments for mental health conditions including depression (search) and post-traumatic stress disorder (search) (PTSD (search)).
Upcoming Catalysts and Pipeline Development
Despite the market reaction, Compass Pathways continues to advance its clinical program with two additional Phase 3 trials testing COMP360 for treatment-resistant depression (search). The company expects 26-week readout data from these trials in 2026, which will provide crucial long-term efficacy and safety data for potential FDA approval.
Earlier trial data showed promising effects at six and twelve weeks, though investors remain cautious about long-term durability and patient variability. Some concerns have been raised about the treatment's potential selectivity and reports of adverse events in prior trials. The company is also pursuing studies for PTSD (search) treatment applications.
Financial Position and Operational Runway
Compass Pathways reported $260.1 million in cash and cash equivalents in Q1 2025, secured through multiple financing mechanisms including a private investment in public equity (PIPE) deal, a loan agreement with Hercules Capital, and an at-the-market (ATM) offering program.
With a current quarterly cash burn of approximately $49.6 million—comprising $30.9 million in research and development expenses and $18.7 million in general and administrative costs—the company projects its existing cash reserves will support operations through the second half of 2026. This timeline strategically aligns with the anticipated data release from its ongoing Phase 3 COMP006 trial.
Market Valuation and Analyst Outlook
Following the stock decline, Compass Pathways' market capitalization stands at $248 million, with shares down 54% over the past 52 weeks and 27% year-to-date. The correction has resulted in a more attractive valuation, with a price-to-book ratio of 1.31x, significantly below the sector median of 2.7x.
Wall Street analysts maintain confidence in the company's prospects, with a consensus "Strong Buy" rating. Among the 10 analysts covering the stock, eight rate it a "Strong Buy," one assigns a "Moderate Buy," and one rates it a "Hold." The 12-month average price target of $16.40 implies upside potential of 483% from current levels.
The psychedelic medicine sector continues to attract attention as an innovative approach to treating mental health conditions, though regulatory hurdles and clinical uncertainty remain significant challenges for companies pursuing this therapeutic pathway.